The estimation of adhesion molecules sICAM-1, sICAM-2, sVCAM-1, sCD44 ST, sCD44 V5 and dendritic cells function in children with malignancies

J. Weclawek-Tompol, A. Chybicka, B. Rybka, R. Ryczan, D. Noworolska, J. Boguslawska-Jaworska

Department of Children Hematology and Oncology, Medical University of Wroclaw, Poland.

AIM: Total number of 39 children with malignancies were included to the study: in 11 patients (16 month end 16 years (median 11 years) dendritic cells function were analyse, in 28 patients a concentration of adhesion molecules was examined. METHODS: Peripheral bloods was collected at time of diagnosis and during chemotherapy and analysed with used flow cytometric analysis. Quantities of dendritic cells (CD11c+HLA-DR+CD83+CD86+) were examined. Phenotypic populations of elementary lymphocytes (CD3, CD4, CD8, CD16, CD19) with take into consideration markers of activation CD23, CD26, CD28, HLA-DR was analysed. Dendritic cells were examined with use specific markers for distinct blood dendritic cell population: BDCA-1, BDCA-2, BDCA-3. THE RESULTS: of or study showed decreased level of blood dendritic cells in our patients comparison with control group. In children with solid tumours before therapy was founded higher the values of adhesion molecules in comparing to control group (e.g. sICAM-1 442,05 v 184,77 ng/ml). During chemotherapy and after cessation of the therapy, the values of adhesion molecules were higher than of the control group (e.g. sICAM-1 325,30 v 184,77 ng/ml and 315 ng/ml). In the patients with disseminated disease was observed higher-level adhesion molecules in comparing to patients with localized disease. CONCLUSION: It seems that evaluation of adhesion molecules and dendritic cells function could be useful in monitoring of therapy in children with malignancies.

For more information, contact

Paper presented at the International Symposium on Predictive Oncology and Intervention Strategies; Paris, France; February 9 - 12, 2002; in the section on Predictive Markers.